ETHAN - ET for Male BC
NCT05501704
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: Tamoxifen Anastrozole Degarelix Abemaciclib
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Male Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Hormone Receptor Negative Breast Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Jose Pablo Leone
- Last updated on ClinicalTrials.gov
- August 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- Georgetown University Medical Center · Washington D.C., DC
Florida · 1
- Mayo Clinical Hospital Florida · Jacksonville, FL
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
North Carolina · 1
- UNC Lineberger Comprehensive Cancer Center · Chapel Hill, NC
Pennsylvania · 2
- University of Pennsylvania, Abramson Cancer Center · Philadelphia, PA
- University of Pittsburgh Cancer Institute · Pittsburgh, PA
Tennessee · 1
- Vanderbilt Cancer Center · Nashville, TN
Texas · 1
- M. D. Anderson Cancer Center at University of Texas · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.